A142760 Stock Overview
Bioleaders Corporation engages in the medicine and consumer business in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bioleaders Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,350.00 |
| 52 Week High | ₩4,560.00 |
| 52 Week Low | ₩1,500.00 |
| Beta | 0.77 |
| 1 Month Change | 35.08% |
| 3 Month Change | 91.21% |
| 1 Year Change | -23.78% |
| 3 Year Change | -41.64% |
| 5 Year Change | -72.08% |
| Change since IPO | -76.41% |
Recent News & Updates
Shareholder Returns
| A142760 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 24.1% | -4.0% | -3.3% |
| 1Y | -23.8% | 0.7% | 1.2% |
Return vs Industry: A142760 underperformed the KR Biotechs industry which returned 0.7% over the past year.
Return vs Market: A142760 underperformed the KR Market which returned 1.2% over the past year.
Price Volatility
| A142760 volatility | |
|---|---|
| A142760 Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.9% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A142760's share price has been volatile over the past 3 months.
Volatility Over Time: A142760's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 45 | Andy Chul | www.bioleaders.com |
Bioleaders Corporation engages in the medicine and consumer business in South Korea. The company offers P53, a target anti-cancer drug. Its pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy.
Bioleaders Corporation Fundamentals Summary
| A142760 fundamental statistics | |
|---|---|
| Market cap | ₩109.66b |
| Earnings (TTM) | -₩6.20b |
| Revenue (TTM) | ₩18.25b |
6.0x
P/S Ratio-17.7x
P/E RatioIs A142760 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A142760 income statement (TTM) | |
|---|---|
| Revenue | ₩18.25b |
| Cost of Revenue | ₩12.70b |
| Gross Profit | ₩5.54b |
| Other Expenses | ₩11.75b |
| Earnings | -₩6.20b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -189.53 |
| Gross Margin | 30.37% |
| Net Profit Margin | -34.00% |
| Debt/Equity Ratio | 16.5% |
How did A142760 perform over the long term?
See historical performance and comparison